Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 19/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 16/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23780445 | 0.83 | HDAC6 (0.50) | HDAC6HDAC1HDAC8HDAC4PTGS2 | |
| SCHEMBL23780452 | 0.82 | HDAC6 (0.47) | HDAC6HDAC1HDAC8HDAC4PTGS2 | |
| SCHEMBL30172454 | 0.82 | HDAC6 (0.47) | HDAC6HDAC1HDAC8HDAC4PTGS2 | |
| SCHEMBL23780442 | 0.81 | HDAC1 (0.69) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL30172415 | 0.80 | HDAC6 (0.45) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL23780444 | 0.80 | HDAC6 (0.45) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL23780406 | 0.78 | HDAC6 (0.50) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL23780407 | 0.75 | HDAC6 (0.50) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL23291999 | 0.74 | MPO (0.44) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL23780424 | 0.74 | HDAC6 (0.49) | HDAC6HDAC1HDAC8HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187712-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2025-01-07 | — | — | US | claimed |
| EP-3814343-B1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS INC (US) | 2023-01-11 | — | — | EP | claimed |
| US-12187712-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-3814343-B1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS INC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20210276991-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2021-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187712-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, MYLK2 | HDAC6 233/4885HDAC1 203/4885HDAC8 647/4885 |
| US-20210276991-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | HDAC6 233/4885HDAC1 203/4885HDAC8 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.